You just read:

Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia

News provided by

Protagonist Therapeutics, Inc.

Dec 03, 2019, 07:00 ET